Home / Endocrinology

Endocrinology

FDA to Review Regeneron’s sBLA of Eylea Injection for the Treatment of Diabetic Retinopathy

TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA®(aflibercept) Injection for the treatment of diabetic retinopathy (DR), the leading cause of vision loss for patients with diabetes. The target action …

Read More »

Merck and Healthy Interactions Launch Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management

KENILWORTH, N.J., Aug. 17, 2018 /PRNewswire/ — Healthy Interactions, a global leader in health education, in collaboration with Merck (NYSE : MRK ), known as MSD outside the United States and Canada, today announced the launch of map4health™ – a digital platform and mobile application in the U.S. that was …

Read More »

Novo Nordisk Acquires Ziylo, Gaining Innovative Technology Platform that Could Accelerate Development of New Diabetes Treatment

BRISTOL and COPENHAGEN, 17 August 2018 ­- Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology – …

Read More »

PDL BioPharma Acquires Depomed’s Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

INCLINE VILLAGE, Nev., Aug. 2, 2018 /PRNewswire/ — PDL BioPharma, Inc. (“PDL”) (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the “Royalty Agreement”) with Depomed, Inc. (“Depomed”) under which PDL acquired all of Depomed’s remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to $20 million.  Under …

Read More »

Boehringer Ingelheim and Lilly Announce Top-Line Phase 3 Data Results for Empagliflozin as Adjunct to Insulin in Type 1 Diabetes

INGELHEIM, Germany and INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE phase III program, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, …

Read More »

FDA Approves World’s First Long-Term Implantable Continuous Glucose Monitoring System for Patients with Diabetes

The U.S. Food and Drug Administration today approved the Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to …

Read More »

FDA Permits Marketing of Artificial Intelligence-Based Device to Detect Certain Diabetes-Related Eye Problems

The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes. Diabetic retinopathy occurs when high levels of blood sugar lead to damage in the …

Read More »

FDA Approves Bydureon for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON® (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with inadequate glycemic control. BYDUREON is approved for adults with T2D whose blood sugar remains uncontrolled on …

Read More »

FDA Approves Merck and Pfizer’s SGLT2 Drug for Treatment of Type 2 Diabetes

KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved STEGLATROTM(ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) tablets. …

Read More »

FDA Approves Sanofi’s Admelog, a Biosimilar of Humalog

PARIS, Dec. 11, 2017 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Admelog®, the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime. “Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes. Complementing our existing insulin …

Read More »